Bastemir, Mehmet <br/><br/>
The PPAR-gamma activator rosiglitazone fails to lower plasma growth hormone and insulin-like growth factor-1 levels in patients with acromegaly.  [electronic resource] 

 -  Neuroendocrinology  2007 
 - 119-23 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article 
<br/><br/><label>ISSN: </label>1423-0194 
<br/><br/><label>Standard No.: </label>10.1159/000106830  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acromegaly--blood<br/>Adenoma--blood<br/>Adult<br/>Diabetes Mellitus--drug therapy<br/>Female<br/>Growth Hormone-Secreting Pituitary Adenoma--blood<br/>Human Growth Hormone--blood<br/>Humans<br/>Hypoglycemic Agents--administration & dosage<br/>Insulin-Like Growth Factor I--metabolism<br/>Male<br/>Middle Aged<br/>PPAR gamma--agonists<br/>Prospective Studies<br/>Rosiglitazone<br/>Thiazolidinediones--administration & dosage<br/>Treatment Failure